Ensysce Biosciences reports Q4 2025 net loss of $2.8M, advances PF614 Phase 3 trial

Ensysce Biosciences, Inc.

Cash $4.3M at Dec 31, 2025; net loss for 2025 $10.2M vs $8.0M in 2024.
R&D expenses rose $3.2M to $10.4M due to clinical programs for PF614 and PF614-MPAR.
Enrolled first patient in Phase 3 trial (PF614-301) for moderate-to-severe post-surgical pain.
FDA supports streamlined 505(b)(2) pathway for PF614-MPAR with overdose-protection labeling.
USPTO allowed new MPAR patent covering composition-of-matter and method-of-use claims through 2042.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-26-013622
form_type: 8-K
ticker: ENSC
cik: 0001716947
company_name: Ensysce Biosciences, Inc.
filed_at: 2026-03-30T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.988673+00:00
generated_at: 2026-05-15T08:24:28.106786+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.55
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-26-013622
json_url: https://secwatch.observer/filing/0001493152-26-013622.json
markdown_url: https://secwatch.observer/filing/0001493152-26-013622.md
text_url: https://secwatch.observer/filing/0001493152-26-013622.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315226013622/0001493152-26-013622-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315226013622/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-26-013622

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.